Who are Aatezolizumab plus Bevacizumab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Atezolizumab & Bevacizumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aatezolizumab-plus-bevacizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Aatezolizumab plus Bevacizumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Aatezolizumab plus Bevacizumab (Aatezolizumab plus Bevacizumab) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-L1 inhibitor + VEGF inhibitor combination. Area: Oncology.

phase 2 PD-L1 inhibitor + VEGF inhibitor combination PD-L1 and VEGF Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Aatezolizumab plus Bevacizumab (Aatezolizumab plus Bevacizumab) — Tae Won Kim. Atezolizumab blocks PD-L1 to enhance immune response while bevacizumab inhibits VEGF to reduce tumor angiogenesis, combining immunotherapy with anti-angiogenic therapy.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aatezolizumab plus Bevacizumab TARGET	Aatezolizumab plus Bevacizumab	Tae Won Kim	phase 2	PD-L1 inhibitor + VEGF inhibitor combination	PD-L1 and VEGF
Atezolizumab & Bevacizumab	Atezolizumab & Bevacizumab	IRCCS Azienda Ospedaliero-Universitaria di Bologna	phase 3	PD-L1 inhibitor + VEGF inhibitor combination	PD-L1 and VEGF

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-L1 inhibitor + VEGF inhibitor combination class)

IRCCS Azienda Ospedaliero-Universitaria di Bologna · 1 drug in this class
Tae Won Kim · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aatezolizumab plus Bevacizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/aatezolizumab-plus-bevacizumab. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab